Head-to-head · WeighScore
Ivim Health vs NuuVim
The verdict
NuuVim takes it — 68.2/100 to 59.6/100.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ivim Health | NuuVim |
|---|---|---|
| WeighScore | 59.6/100 | 68.2/100 |
| Grade | C | C |
| Scorecard rank | #338 | #153 |
| Semaglutide | $149/mo (starting dose, medication and programme fee, compounded) | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | $224/mo (starting dose, medication and programme fee, compounded) | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #338 · C
Strengths
- Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
Where it loses points
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
- Both figures are 'starting at' rates, so the cost of a titrated dose is not published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.